Business
Spectral Diagnostics to Present at Bloom Burton & Co. Healthcare Investor Conference
TORONTO, June 12, 2012 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI, OTCQX: DIAGF) , a Phas...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n\n\nTORONTO, June 12, 2012 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI, OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for\n patients with septic shock, today announced that Dr. Paul Walker, the\n Company's President and Chief Executive Officer, will present at the\n Bloom Burton & Co. Healthcare Investor Conference on Thursday, June 21,\n at 10:00 am Eastern Time. The conference will be held at the Toronto\n Board of Trade in Toronto, Ontario.\n\n\nDr. Walker will provide a corporate update, including information about\n the Company's pivotal sepsis program.\n\n\nThe Bloom Burton & Co. Healthcare Investor Conference brings together\n U.S., Canadian and European investors who are interested in the latest\n developments in the Canadian healthcare sector. Attendees will have an\n opportunity to obtain corporate updates from the premier Canadian\n public and private companies through presentations and break-out Q&A\n sessions.\n\n\nAbout Spectral Diagnostics\nSpectral is a Phase III company seeking U.S. FDA approval for its lead\n theranostics product for the treatment for severe sepsis and septic\n shock. Toraymyxin is a therapeutic hemoperfusion device that removes\n endotoxin, which can cause sepsis, from the bloodstream. Directed by\n the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared\n diagnostic for the risk of developing sepsis. Spectral's EUPHRATES\n trial is the world's first theranostics trial in the area of sepsis.\n\n\nToraymyxin has been approved for therapeutic use in Japan and Europe,\n and has been used safely and effectively in more than 80,000 patients\n to date. In March 2009, Spectral obtained the exclusive development and\n commercial rights in the U.S. for Toraymyxin, and in November 2010,\n signed an exclusive distribution agreement for this product in Canada.\n More than 250,000 patients are diagnosed with severe sepsis and septic\n shock in North America each year, representing a greater than $1\n billion market opportunity for Spectral. Spectral is listed on the\n Toronto Stock Exchange under the symbol SDI, and on the OTQ QX under\n the symbol DIAGF. For more information please visit www.spectraldx.com\n\n\nAbout Bloom Burton & Co. \nBloom Burton & Co. is Canada's largest and most active\n healthcare-specialized investment ...